Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BaseTIL: TIL Transfer with Nivolumab in Advanced Melanoma
NCT04165967Phase 1Completed
- Sponsor
- University Hospital Basel
- Start
- Sep 2020
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC101 TIL + pembrolizumab in melanoma, sponsored by University Hospital Basel. Primary endpoints: Number of Adverse Events at 3 months, Change in body temperature and 4 more. Started Sep 2020; status: completed.
02
Drugs
GC101 TIL + pembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04165967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04165967.